comparemela.com

Latest Breaking News On - Kadimastem - Page 1 : comparemela.com

iTolerance, Inc and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes and Receive US $1 0 Million Grant from the BIRD Foundation

MIAMI, FL / ACCESSWIRE / May 18, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

DGAP-News: Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment Seite 1

09.08.2022 - DGAP-News: Kadimastem Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment 09.08.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Kadimastem Ltd. (TASE: KDST), a clinical stage . Seite 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.